TABLE 8

Products, inhalers, and characteristics of short-acting combination therapies

Prescribing Information: www.accessdata.fda.gov/scripts/cder/daf/ (USA), www.fachinfo.de/(EU, Germany), www.medicines.org.uk/emc/(UK).

Active IngredientIndication (Brand)aInhalerDelivered DosePharmacological ProfileClinical Summary
Ipratropium (bromide monohydrate) + salbutamol (sulfate)Treatment of symptoms of COPD
Generics

Combivent Respimat
Combivent UDV
and generics
pMDI
SMI

UDV/
Nebulizer
18 μg (ipr-br) + 103 μg (sal-su)/puff × 2 puffs, maximum 12 puffs/day
20 μg (ipr-br) + 120 μg (sal-su)/actuation, 4 ×/day maximum 6
0.52 mg (ipr-br) + 3 mg
(sal-su)/2.5 ml, maximum 6
SAMA
and SABA
For patients on a regular bronchodilator, who require a second bronchodilator
Ipratropium (bromide monohydrate) + fenoterol (hydro-bromide)(EU) Acute treatment of symptoms of asthma (age ≥ 6 y) and COPD
Berodual N MDI Berodual Respimat
(age ≥ 18 y)
Berodual UDV
(age ≥ 12 y)
pMDI
(metered dose)
Soft mist inhaler
UDV/Nebulizer
21 μg (ipr-br) + 50 μg (fen- br)/puff, 2 puffs,
maximum 8 puffs/day
20 μg (ipr-br) + 50 μg (fen- br)/ actuation, maximum 4–6 act./day
26.1µg (ipr-br) + 50 µg (fen-br)/0.1 ml, 1–2 portions, in severe cases up to 40 portions per treatment
SAMA
and SABA
Rescue for COPD and asthma
  • aThe brand names are not meant to be an exhaustive list; they are provided for illustrative purposes, as different products containing the same drugs may have different quantitative compositions, formulations, devices, and overall characteristics.